JUNOVAN

Preparations for medical or veterinary use, namely muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), N-acetylmuramyl-L-ananyl-D-isoglutaminyl-L-alanine-2 (l,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy) ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all these goods specifically used for cancer control treatment, antiviral treatment, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations for anti-cancer and antiviral therapies, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy